Simpler Grants.gov #FOR-NS-25-002

NIH Forecast: Non-addictive Analgesic Therapeutics Research and Development Funding

This opportunity is a forecasted research funding initiative from the National Institutes of Health (NIH) focused on developing non-addictive analgesic therapeutics for pain treatment. - Government Buyer: - United States Department of Health and Human Services - National Institutes of Health (NIH), with participation from twelve NIH Institutes (NINDS, NEI, NHLBI, NIA, NIAAA, NIAMS, NICHD, NIDCR, NIDDK, NIDA, NCCIH, NCI) - Products/Services Requested: - Research and development of small molecule and biologic non-addictive analgesic therapeutics - Activities include early optimization, preclinical development, and readiness for Phase II clinical studies - Projects must be able to enter first-in-human (Phase I) studies by the end of the grant period - Unique/Notable Requirements: - Collaborations with NIH-funded consultants and contract research organizations (CROs) are encouraged - Excludes basic research, therapeutic device development, and clinical studies beyond Phase I - No specific products, part numbers, or quantities are listed as this is a research grant - OEMs: - No specific OEMs are named, as this is a research funding opportunity for new therapeutic development

Description

Twelve NIH Institutes intend to publish a Notice of Funding Opportunity to solicit applications for research focused on the discovery and development of small molecule and biologic non-addictive analgesic therapeutics to treat pain. The program aims to accelerate optimization and development of early therapeutic molecules and facilitate readiness for Phase II clinical studies. Funding supports drug discovery and development activities conducted in researchers' laboratories, encouraging collaborations with NIH-funded consultants and CROs. The scope includes early optimization through Phase I development, expecting projects to enter first-in-human studies by the grant period's end. This is a milestone-driven, phased, cooperative agreement involving NIH program staff participation, excluding basic research, therapeutic device development, and clinical studies beyond Phase I.

View original listing